... for hdPS deciles for the all-cause mortality model. Abbreviations: CI = confidence interval; HR = hazard ratio; hdPS = high-dimensional propensity score ...
SUPPLEMENTARY DATA Supplementary Table S1. Hazard ratios for all outcomes associated with glyburide or glimepiride, compared with pancreas specific, short-acting sulfonylureas (gliclazide, glipizide, tolbutamide) in patients with type 2 diabetes. No. of patients
No. of events
Personyears
Incidence rate (95% CI) [per 1000 person-years]
Crude HR (95% CI)
Adjusted HR (95% CI) *
15,611
223
18,361
12.1 (10.6-13.8)
1.00 (reference)
1.00 (reference)
Glyburide
917
9
1088
8.3 (3.8-15.7)
0.68 (0.35-1.33)
0.82 (0.42-1.60)
Glimepiride
944
13
1312
9.9 (5.3-16.9)
0.83 (0.48-1.46)
0.91 (0.52-1.59)
15,549
215
18,316
11.7 (10.2-13.4)
1.00 (reference)
1.00 (reference)
Glyburide
917
10
1082
9.2 (4.4-17.0)
0.79 (0.42-1.49)
1.04 (0.54-1.98)
Glimepiride
940
12
1316
9.1 (4.7-15.9)
0.79 (0.44-1.41)
0.86 (0.48-1.54)
15,512
69
18,368
3.8 (2.9-4.8)
1.00 (reference)
1.00 (reference)
Glyburide
917
6
1088
5.5 (2.0-12.0)
1.45 (0.63-3.34)
2.32 (0.98-5.50)
Glimepiride
945
12
1324
9.1 (4.7-15.8)
2.43 (1.32-4.49)
3.19 (1.71-5.96)
15,647
417
18,498
22.5 (20.4-24.8)
1.00 (reference)
1.00 (reference)
Glyburide
917
16
1089
14.7 (8.4-23.9)
0.65 (0.40-1.07)
0.99 (0.60-1.65)
Glimepiride
944
25
1330
18.8 (12.2-27.7)
0.85 (0.57-1.27)
1.03 (0.69-1.55)
15,405
1233
18,320
67.3 (63.6-71.2)
1.00 (reference)
1.00 (reference)
Glyburide
917
39
1089
35.8 (25.5-49.0)
0.53 (0.39-0.73)
0.80 (0.58-1.10)
Glimepiride
944
59
1330
44.4 (33.8-57.2)
0.68 (0.53-1.89)
0.82 (0.63-1.07)
Exposure Myocardial infarction Specific, short-acting sulfonylureas
Ischemic Stroke Specific, short-acting sulfonylureas
Hypoglycemia Specific, short-acting sulfonylureas
Cardiovascular Death Specific, short-acting sulfonylureas
All-Cause Mortality Specific, short-acting sulfonylureas
*
Adjusted for hdPS deciles and history of the outcomes for the acute myocardial infarction and the ischemic stoke model; Adjusted for hdPS quintiles for the severe hypoglycemia model; Adjusted for hdPS deciles and history of acute myocardial infarction or ischemic stroke for the cardiovascular death model; Adjusted for hdPS deciles for the all-cause mortality model. Abbreviations: CI = confidence interval; HR = hazard ratio; hdPS = high-dimensional propensity score
©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-0595/-/DC1
SUPPLEMENTARY DATA Supplementary Table S2. Hazard ratios for all outcomes associated with pancreas non-specific, long-acting sulfonylureas (glyburide, glimepiride) compared with pancreas specific, short-acting sulfonylureas (gliclazide, glipizide, tolbutamide) in patients with type 2 diabetes (excluding patients with a history of the outcomes).
Exposure
No. of patients
No. of events
Personyears
Incidence rate (95% CI) [per 1000 person-years]
Crude HR (95% CI)
Adjusted HR (95% CI) *
13,979
169
16,409
10.3 (8.8-12.0)
1.00 (reference)
1.00 (reference)
1686
18
2181
8.3 (4.9-13.0)
0.81 (0.50-1.32)
0.88 (0.54-1.44)
14,396
149
16,875
8.8 (7.5-10.4)
1.00 (reference)
1.00 (reference)
1738
17
2253
7.5 (4.4-12.1)
0.86 (0.52-1.42)
1.03 (0.61-1.72)
15,431
69
18,294
3.8 (2.9-4.8)
1.00 (reference)
1.00 (reference)
1845
18
2406
7.5 (4.4-11.8)
1.99 (1.18-3.34)
2.84 (1.65-4.90)
13,053
255
15,284
16.7 (14.7-18.9)
1.00 (reference)
1.00 (reference)
1592
30
2070
14.5 (9.8-20.7)
0.87 (0.60-1.27)
1.14 (0.78-1.68)
Acute Myocardial Infarction Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Ischemic Stroke Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Severe Hypoglycemia Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Cardiovascular Death Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas *
Adjusted for hdPS deciles for the acute myocardial infarction, ischemic stroke, and cardiovascular death models; Adjusted for hdPS quintiles for the severe hypoglycemia model. Abbreviations: CI = confidence interval; HR = hazard ratio; hdPS = high-dimensional propensity score
©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-0595/-/DC1
SUPPLEMENTARY DATA Supplementary Table S3. Hazard ratios for all outcomes associated with pancreas non-specific, long-acting sulfonylureas (glyburide, glimepiride) compared with pancreas specific, short-acting sulfonylureas (gliclazide, glipizide) in patients with type 2 diabetes (excluding tolbutamide users).
Exposure
No. of patients
No. of events
Personyears
Incidence rate (95% CI) [per 1000 person-years]
Crude HR (95% Adjusted HR (95% CI) * CI)
15,084
209
17,631
11.9 (10.3-13.6)
1.00 (reference)
1.00 (reference)
1860
22
2428
9.1 (5.7-13.7)
0.78 (0.50-1.20)
0.87 (0.56-1.37)
15,013
199
17,567
11.3 (9.8-13.0)
1.00 (reference)
1.00 (reference)
1858
22
2420
9.1 (5.7-13.8)
0.81 (0.52-1.25)
0.94 (0.60-1.48)
15,002
67
17,627
3.8 (2.9-4.8)
1.00 (reference)
1.00 (reference)
1863
18
2435
7.4 (4.4-11.7)
1.94 (1.16-3.27)
2.65 (1.53-4.60)
15,069
388
17,705
21.9 (19.8-24.2)
1.00 (reference)
1.00 (reference)
1859
41
2440
16.8 (12.1-22.8)
0.78 (0.56-1.07)
1.06 (0.76-1.47)
14,945
1191
17,628
67.6 (63.8-71.5)
1.00 (reference)
1.00 (reference)
1861
99
2440
40.6 (33.0-49.4)
0.61 (0.50-0.75)
0.83 (0.67-1.02)
Acute Myocardial Infarction Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Ischemic Stroke Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Severe Hypoglycemia Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Cardiovascular Death Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas All-Cause Mortality Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas *
Adjusted for hdPS deciles and history of the outcomes for the acute myocardial infarction and ischemic stroke models; Adjusted for hdPS quintiles for the severe hypoglycemia model; Adjusted for hdPS deciles and history of acute myocardial infarction or ischemic stroke for the cardiovascular death model; Adjusted for hdPS deciles for the all-cause mortality model. Abbreviations: CI = confidence interval; HR = hazard ratio; hdPS = high-dimensional propensity score
©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-0595/-/DC1
SUPPLEMENTARY DATA Supplementary Table S4. Hazard ratios for all outcomes associated with pancreas non-specific, long-acting sulfonylureas (glyburide, glimepiride) compared with pancreas specific, short-acting sulfonylureas (gliclazide, glipizide, tolbutamide) in patients with type 2 diabetes (60-day grace period).
Exposure
No. of patients
No. of events
Personyears
Incidence rate (95% CI) [per 1000 person-years]
Crude HR (95% CI)
Adjusted HR (95% CI) *
15,513
336
26,728
12.6 (11.3-14.0)
1.00 (reference)
1.00 (reference)
1856
39
3207
12.2 (8.6-16.6)
0.97 (0.69-1.35)
1.10 (0.78-1.54)
15,635
307
26,854
11.4 (10.2-12.8)
1.00 (reference)
1.00 (reference)
1862
27
3241
8.3 (5.5-12.1)
0.73 (0.50-1.09)
0.83 (0.55-1.24)
15,679
127
27,064
4.7 (3.9-5.6)
1.00 (reference)
1.00 (reference)
1861
21
3245
6.5 (4.0-9.9)
1.38 (0.87-2.19)
1.86 (1.15-2.99)
15,700
633
27,153
23.3 (21.5-25.2)
1.00 (reference)
1.00 (reference)
1860
64
3254
19.7 (15.1-25.1)
0.85 (0.65-1.10)
1.05 (0.81-1.37)
15,510
1858
26,983
68.9 (65.8-72.1)
1.00 (reference)
1.00 (reference)
1862
154
3256
47.3 (40.1-55.4)
0.69 (0.59-0.81)
0.87 (0.73-1.02)
Acute Myocardial Infarction Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Ischemic Stroke Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Severe Hypoglycemia Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Cardiovascular Death Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas All-Cause Mortality Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas *
Adjusted for hdPS deciles and history of the outcomes for the acute myocardial infarction and ischemic stroke models; Adjusted for hdPS quintiles for the severe hypoglycemia model; Adjusted for hdPS deciles and history of acute myocardial infarction or ischemic stroke for the cardiovascular death model; Adjusted for hdPS deciles for the all-cause mortality model. Abbreviations: CI = confidence interval; HR = hazard ratio; hdPS = high-dimensional propensity score
©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-0595/-/DC1
SUPPLEMENTARY DATA Supplementary Table S5. Hazard ratios for all outcomes associated with pancreas non-specific, long-acting sulfonylureas (glyburide, glimepiride) compared with pancreas specific, short-acting sulfonylureas (gliclazide, glipizide, tolbutamide) in patients with type 2 diabetes (intention-to-treat analysis).
Exposure
No. of patients
No. of events
Personyears
Incidence rate (95% CI) [per 1000 person-years]
Crude HR CI)
(95%
Adjusted HR (95% CI) *
15,665
189
14,481
13.1 (11.3-15.1)
1.00 (reference)
1.00 (reference)
1861
20
1759
11.4 (6.9-17.6)
0.87 (0.55-1.38)
1.04 (0.65-1.67)
15,600
177
14,436
12.3 (10.5-14.2)
1.00 (reference)
1.00 (reference)
1863
14
1765
7.9 (4.3-13.3)
0.65 (0.38-1.12)
0.75 (0.43-1.30)
15,514
62
14,394
4.3 (3.3-5.5)
1.00 (reference)
1.00 (reference)
1863
9
1762
5.1 (2.3-9.7)
1.21(0.60-2.44)
1.51 (0.73-3.12)
15,640
344
14,514
23.7 (21.3-26.3)
1.00 (reference)
1.00 (reference)
1861
37
1766
21.0 (14.8-28.9)
0.89 (0.63-1.24)
1.21 (0.85-1.72)
15,505
1257
14,420
87.2 (82.4-92.1)
1.00 (reference)
1.00 (reference)
1862
105
1767
59.4 (48.6-71.9)
0.68 (0.56-0.84)
0.98 (0.80-1.20)
Acute Myocardial Infarction Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Ischemic Stroke Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Severe Hypoglycemia Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas Cardiovascular Death Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas All-Cause Mortality Specific, short-acting sulfonylureas Non-specific, long-acting sulfonylureas *
Adjusted for hdPS deciles and history of the outcomes for the acute myocardial infarction and ischemic stroke models; Adjusted for hdPS quintiles for the severe hypoglycemia model; Adjusted for hdPS deciles and history of acute myocardial infarction or ischemic stroke for the cardiovascular death model. Adjusted for hdPS deciles for the all-cause mortality model. Abbreviations: CI = confidence interval; HR = hazard ratio; hdPS = high-dimensional propensity score
©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-0595/-/DC1
